<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04189003</url>
  </required_header>
  <id_info>
    <org_study_id>APHP180166</org_study_id>
    <secondary_id>APHP180166</secondary_id>
    <nct_id>NCT04189003</nct_id>
  </id_info>
  <brief_title>Molecular Signatures of HPV+ ORL Cancers (OROPAP)</brief_title>
  <acronym>OROPAP</acronym>
  <official_title>Identification of Specific Molecular Signatures by Capture-HPV and Next-generation Sequencing in HPV-induced Oropharyngeal Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to identify HPV molecular signature in head and neck cancer to
      establish a new classification for positive human papillomavirus oropharyngeal tumor
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OROPAP is a monocentric exploratory study with retrospective inclusion of patients.

      The retrospective study focus on patients who have had surgery for HPV-positive oropharyngeal
      tumors whose survival is at least 2 year.

      Frozen and or FFPE biopsies of these tumors and frozen blood samples are available via the
      HEGP biological resources platform.

      The HPV molecular signatures will be identified by the capture-HPV technique.

      For each patient, clinical-anatomo-pathological data such as tumor size, tumor stage,
      presence or absence of metastasis, histological stage, different treatment lines and 2-years
      survival data will be collected through the use of data warehouse available on the HEGP.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Description the HPV molecular signatures identified by the Capture-HPV technique and comparison of these signatures with those already described in the classification described in the Holmes et al. in the cervix</measure>
    <time_frame>18 months</time_frame>
    <description>Establish a new classification based on HPV molecular signature for positive human papillomavirus oropharyngeal tumor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of HPV circulating tumoral DNA in peripheral blood by droplet based digital PCR</measure>
    <time_frame>18 months</time_frame>
    <description>Find in the peripheral blood of patients, the presence of circulating tumoral HPV DNA (ctDNA) by droplet based digital PCR and when it is possible compare chromosomal insertion patterns of HPV ct DNA as those found in tumors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlate identified HPV molecular signature with clinical-anatomo-pathological data.</measure>
    <time_frame>18 months</time_frame>
    <description>Look for an association between the presence of specific HPV molecular signatures and clinical-anatomo-pathological data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Death of any cause, or eventual relapse</measure>
    <time_frame>18 months</time_frame>
    <description>Look for an association between the presence of these molecular signatures and the survival of patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of the number of copies of viral genes to the number of cells</measure>
    <time_frame>18 months</time_frame>
    <description>Measure the viral load of HPV in the tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Precise description of HPV insertion localisation in human genome when HPV is integrated</measure>
    <time_frame>18 months</time_frame>
    <description>Identify disrupted metabolic pathways in tumor cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of new HPV viral variants based on complete HPV genome sequencec obtained by Capture-HPV coupled with NGS</measure>
    <time_frame>18 months</time_frame>
    <description>Analyze of complete viral genomes and identify potential variants through sequencing data analysis</description>
  </secondary_outcome>
  <enrollment type="Actual">66</enrollment>
  <condition>Oropharyngeal Cancer</condition>
  <condition>Human Papillomavirus-Related Carcinoma</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Frozen and/or FFPE biopsies of HPV-positive oropharyngeal tumors and frozen blood sample
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with HPV-induced oropharyngeal cancer with survival follow-up greater than 2 years
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with HPV + oropharyngeal cancer

        Exclusion Criteria:

          -  NA
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hélène PÉRÉ, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AP-HP, Hôpital Européen Georges Pompidou</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2019</study_first_posted>
  <last_update_submitted>December 4, 2019</last_update_submitted>
  <last_update_submitted_qc>December 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ORL Cancers</keyword>
  <keyword>HPV+ tumor</keyword>
  <keyword>molecular signature</keyword>
  <keyword>human papillomavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie results in publication could be shared. Individual participant data detailed in meta analysis protocol could be shared</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>one year after the last publication</ipd_time_frame>
    <ipd_access_criteria>Data sharing must be accepted by the sponsor and the PI based on scientific project and scientific involvement of the PI team.
Teams wishing obtain IPD must meet the sponsor and IP team to present scientifics (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractualization</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

